目的 探討鹽酸氯丙嗪聯(lián)合帕洛諾司瓊預(yù)防化療藥物致惡心嘔吐的臨床療效。方法 2014年1月—2014年7月在襄陽(yáng)市中心醫(yī)院行高致吐性化療藥物的住院患者126例,隨機(jī)分為對(duì)照組和治療組,每組63例。對(duì)照組患者在化療第1天,開始化療前30 min靜脈滴注鹽酸帕洛諾司瓊注射液,0.25 mg/次,1次/d,注射時(shí)間30 s以上。治療組在對(duì)照組基礎(chǔ)上肌肉注射鹽酸氯丙嗪注射液25 mg/次。3周為1個(gè)化療周期,兩組在1個(gè)化療周期后觀察惡心、嘔吐的控制率。結(jié)果 對(duì)照組和治療組急性嘔吐控制率分別為76.19%、84.13%,延遲性嘔吐控制率分別為50.79%、63.49%,治療組急性、延遲性嘔吐控制率均顯著高于對(duì)照組,兩組比較差異具有統(tǒng)計(jì)學(xué)意義(P < 0.05)。對(duì)照組和治療組急性惡心控制率分別為58.73%、77.78%,延遲性惡心控制率分別為49.21%、65.08%,兩組比較差異具有統(tǒng)計(jì)學(xué)意義(P < 0.05)。對(duì)照組和治療組急性食欲減退控制率分別為87.30%、90.48%,延遲性食欲減退控制率分別為84.12%、87.30%,兩組比較差異無統(tǒng)計(jì)學(xué)意義。結(jié)論 鹽酸氯丙嗪聯(lián)合帕洛諾司瓊預(yù)防化療藥物致惡心嘔吐具有較好的臨床療效,且不會(huì)增加不良反應(yīng),值得臨床推廣應(yīng)用。

Objective To explore the clinical effect of chlorpromazine hydrochloride combined with palonosetron in preventing nausea and vomiting induced by chemotherapy drugs. Methods Patients (126 cases) with malignant tumor receiving emetogenic chemotherapy in Xiangyang Central Hospital from January 2014 to July 2014 were randomly divided into control and treatment groups, and each group had 63 cases. The patients in the control group were iv administered with Palonosetron Hydrochloride Injection 30 min before chemotherapy at the first day of the chemotherapy, 0.25 mg/time, once daily, and the injection time was more than 30 s. The patients in the treatment group were im administered with Chlorpromazine Hydrochloride Injection at the basis of the control group, 25 mg/time. One course of treatment was 3 weeks, the control rates of nausea and vomiting were observed after one chemotherapy cycle. Results The acute vomiting control rates in the control and treatment groups were 76.19% and 84.13%, respectively, while delayed vomiting control rates in two groups were 50.79% and 63.49%, respectively. The acute and delayed vomiting control rates in treatment group were higher than those in the control group, and there were differences between two groups (P < 0.05). The acute nausea control rates in the control and treatment groups were 58.73% and 77.78%, respectively, while delayed nausea control rates in two groups were 49.21% and 65.08%, respectively, and there were differences between two groups (P < 0.05). The acute nausea control rates in the control and treatment groups were 87.30% and 90.48%, respectively, while delayed nausea control rates in two groups were 84.12% and 87.30%, respectively, and there was no difference between two groups. Conclusion Chlorpromazine hydrochloride combined with palonosetron has the good clinical effect in preventing nausea and vomiting induced by chemotherapy drugs, and will not increase adverse reactions, which is worth clinical promotion.